Pfizer's diversified pipeline and new product launches are driving operational growth. Click here to read more about PFE ...

One of the highest yields you can get right now is from Pfizer (NYSE: PFE). The healthcare giant offers a yield of 6.8%, ...

Pfizer faces challenges from pricing pressures, a 2026 patent cliff, and weak R&D momentum. Click here to find out why I rate ...

Pfizer Inc. (NYSE:PFE) discovers, develops, markets, and sells biopharmaceutical products in the U.S. and internationally. It ...

TORONTO — Health Canada has authorized updated COVID-19 vaccines by Pfizer and BioNTech and by Moderna for use this ...

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal ...

Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...

Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

In terms of liquidity and interest, the mean open interest for Pfizer options trades today is 13596.29 with a total volume of 13,024.00. In the following chart, we are able to follow the development ...

Construction work paused at 235 East 42nd Street, David Werner and Metro Loft’s massive office-to-resi conversion in Midtown ...